Cargando…

Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy

OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Borges, Karin, Kaul, Neha, Germaine, Jack, Kwan, Patrick, O'Brien, Terence J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398112/
https://www.ncbi.nlm.nih.gov/pubmed/30868125
http://dx.doi.org/10.1002/epi4.12308
Descripción
Sumario:OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospective baseline period, people with drug‐resistant epilepsy were randomized in a double‐blind fashion to receive triheptanoin or MCTs. Treatment was titrated over 3 weeks to a maximum of 100 mL/d to be distributed over 3 meals and mixed into food, followed by 12‐week maintenance before tapering. The primary aims were to assess the following: (a) safety by comparing the number of intervention‐related adverse events with triheptanoin vs MCT treatment and (b) adherence, measured as a percentage of the prescribed treatment doses taken. RESULTS: Thirty‐four people were randomized (17 to MCT and 17 to triheptanoin). There were no differences regarding (a) the number of participants completing the study (11 vs 9 participants), (b) the time until withdrawal, (c) the total number of adverse events or those potentially related to treatment, (d) median doses of oils taken (59 vs 55 mL/d, P = 0.59), or (e) change in seizure frequency (54% vs 102%, P = 0.13). Please note that people with focal unaware seizures were underrepresented in the triheptanoin treatment arm (P = 0.04). The most common adverse events were gastrointestinal disturbances (47% and 62.5% of participants). Five people taking on average 0.73 mL/kg body weight MCTs (0.64 mL/kg median) and one person taking 0.59 mL/kg triheptanoin showed >50% reduction in seizure frequency, specifically focal unaware seizures. SIGNIFICANCE: Add‐on treatment with MCTs or triheptanoin was feasible, safe, and tolerated for 12 weeks in two‐thirds of people with treatment‐resistant epilepsy. Our results indicate a protective effect of MCTs on focal unaware seizures. This warrants further study.